NEWS & EVENTS
Immunicom Hosts 1st Annual Global Immunopheresis Conference
This event provided a forum for oncology clinical leaders to meet, discuss and learn about Immunicom's novel, cutting-edge immunotherapy − Immunopheresis™. The conference was a collaborative event involving Immunicom's global partners and focused on therapeutic apheresis as a viable clinical approach in oncology that potentially represents a less-costly innovation than currently-available therapies with the promise to enhance patient care and quality of life.
Immunicom Secures
$11 Million in Series B Investment Round
Immunicom raised $11 million in a Series B investment round. Several private equity family offices participated in the Series B financing which now increases Immunicom's overall capital raised to $20 million."Proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial we began May 31, while also fueling continued expansion of Immunicom's global strategic partnerships," said Amir Jafri, the company's Founder and CEO.
Immunotherapy Product Receives F.D.A. Breakthrough Device Designation
Immunicom has achieved Breakthrough Device designation! To achieve Breakthrough Device designation, a technology must demonstrate compelling potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives
Immunicom successfully completes 300-treatment
pre-clinical canine cancer trial
February
2016
​Tell people more about the services you offer. Use this repeating layout to display content. It’s an easy way to keep your customers up to date with what’s happening. Want to make this content your own? Simple drag and drop elements like text, images and links, or connect to data from your collection.
August
2018
Immunicom is excited to share with a personally invited peer-reviewed article by the Journal of Translational Medicine. This Hot Topic article describes the scientific advancements of Immunicom's technology- authored by Immunicom's head scientist, Dr. Steven Josephs, and co-authors include Immunicom's CEO, CCO, and the Journal's Editor-in-Chief, Dr. Franco Marincola.
Immunicom expands relationship with Terumo BCT, to support collaboration with CHIPSA oncology hospital
December
2017
Immunicom is excited to collaborate with CHIPSA oncology hospital to begin human clinical trials. Additionally, Immunicom's growing relation with Terumo BTC allows for more extensive research and development of the device.
Immunicom presents the results of the canine clinical study at World Vaccine Immunology Conference
December
2017
The World Vaccine Immunology Conference welcomes Immunicom to explore the topics of cancer immunotherapy, clinical trials & development with over150 speakers.
David Schlotterbeck, former Vice Chairman of Cardinal Health, joins Immunicom's Board of Directors as Chairman of the Board
December
2017
Immunicom is excited to welcome David Schlotterbeck - a technology leader with over 45 years of healthcare experience.
Immunicom CEO Leads Impactful & Important Roundtable & Panel Discussion with Key Industry Innovators at the C3 US-Arab Healthcare Business Summit in NYC
September
2019
Immunicom gained an additional $1.85 million towards Series B investment round. This increases Immunicom's overall capital raised to $21.85 million.
Immunicom Secures an Additional $1.85 Million Bringing in Series B Funding to $12.85 Million
September
2019
Immunicom gained an additional $1.85 million towards Series B investment round. This increases Immunicom's overall capital raised to $21.85 million.
Immunicom hires Raju Chauhan as Vice President of Program Management
September
2019
With over 30 years of experience managing teams across the globe, Immunicom is excited to add Raju Chauhan to the team.
Immunicom hosts 1st Annual Global Immunopheresis Conference in Krakow, Poland
July - August
2019
This event provided a forum for oncology clinical leaders to meet, discuss and learn about Immunicom's novel, cutting-edge immunotherapy − Immunopheresis™. The conference was a collaborative event involving Immunicom's global partners and focused on therapeutic apheresis as a viable clinical approach in oncology that potentially represents a less-costly innovation than currently-available therapies with the promise to enhance patient care and quality of life.
Immunicom Secures $11 Million in Series B Investment Round
July
2019
Immunicom raised $11 million in a Series B investment round. Several private equity family offices participated in the Series B financing which now increases Immunicom's overall capital raised to $20 million."Proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial we began May 31, while also fueling continued expansion of Immunicom's global strategic partnerships," said Amir Jafri, the company's Founder and CEO.
First Patient Enrollment in Mutli-Center Triple Negative Breast Cancer Clinical Trial
June
2019
This randomized, multi-center, TNBC clinical study compares Immunopheresis™ alone and its use in combination with low-dose paclitaxel and carboplatin weekly chemotherapy, versus a control arm of low-dose chemotherapy. Immunicom's Immunopheresis therapy is a revolutionary new non-drug, blood-filtering immunotherapy treatment, with the potential to effectively treat a wide variety of cancer types more effectively and with fewer side effects, including those that have failed response to other treatment approaches.
01/
Immunotherapy Product Receives F.D.A Breakthrough Device Designation
02/
Journal of Translation Medicine: "Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic
03/
Immunicom's Secures
$11 Million in Series B Investment Round
04/
First Patient Enrollment in Multi-Center Triple Negative Breast Cancer Clinical Trial
Immunicom expands relationship with Terumo BCT, to support collaboration with CHIPSA oncology hospital
December
2017
Immunicom is excited to collaborate with CHIPSA oncology hospital to begin human clinical trials. Additionally, Immunicom's growing relation with Terumo BTC allows for more extensive research and development of the device.
David Schlotterbeck, former Vice Chairman of Cardinal Health, joins Immunicom's Board of Directors as Chairman of the Board
September
2017
Immunicom is excited to welcome David Schlotterbeck - a technology leader with over 45 years of healthcare experience.
Amir Jafri, President and CEO of Immunicom, presents during the 35th Annual J.P. Morgan Healthcare Conference
January
2017
With over 10,000 attendees and over 450 public and private companies, the annual J.P. Morgan Healthcare Conference is one of the largest healthcare investment conferences in the industry.
​Dr. Gary Pace appointed as a member of Immunicom’s Board of Directors.
August
2016
Dr. Gary Pace, a seasoned bio-pharmaceutical executive with over 30 years of experience in the industry joins Immunicom's Board of Directors.
Immunicom enters an exclusive licensing agreement for University of California, San Diego for targeted molecule delivery technology.
December
2017
Immunicom enters an exclusive licensing agreement with University of California, San Diego for targeted molecule delivery technology
Immunicom successfully completes 300-treatment pre-clinical canine cancer trial
February
2016
The dogs in the trial were stage III or IV patients which had failed standard therapeutic approaches. Overall, 50–60% of the patients treated were observed to have either stable disease or partial responses by RECIST Criteria during treatment with one patient having experienced a complete response with clearance of metastases.
Immunicom completes $5.5M Series A Preferred Stock financing
December
2015
Immunicom completes $5.5M Series A Preferred Stock financing.
Immunicom begins canine cancer pre-clinical trial
​
May
2014
Immunicom begins clinical trial in partnership with California Veterinary Specialists Angel Care Center and University of Pennsylvania School of Veterinary Medicine.
Immunicom signs strategic partnership agreement with Terumo BCT, a subsidiary of Terumo
January 2014
Terumo BCT is one of Japan's largest medical technology companies- an industry-leading specialist for therapeutic apheresis machines that serves in more than 130 countries